Luoxin Health Technology Development (Beijing) Co., Ltd. announced that it will receive CNY 127.90 million on September 14, 2022. The transaction will include participation from returning investors Deyi (Zhuhai) Capital Management Co., Ltd, and Luoxin Pharmaceuticals Group Stock Co., Ltd. The transaction has been approved by the 25th session of its 4th directorate, 21st session of its 4th supervisory board of the company. On closing Luoxin Health Technology Development (Beijing) Co., Ltd. stake will decrease from 83.33% to 51%.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.92 CNY | -1.01% | +0.20% | -8.21% |
1st Jan change | Capi. | |
---|---|---|
-8.21% | 738M | |
+39.22% | 731B | |
+32.06% | 586B | |
-7.85% | 348B | |
+15.48% | 319B | |
-0.12% | 273B | |
+13.43% | 235B | |
+7.48% | 202B | |
-6.95% | 203B | |
-3.37% | 158B |
- Stock Market
- Equities
- 002793 Stock
- News Luoxin Pharmaceuticals Group Stock Co., Ltd.
- Luoxin Health Technology Development Co., Ltd. announced that it expects to receive CNY 127.9 million in funding from Deyi Investment Management Co., Ltd., Luoxin Pharmaceuticals Group Stock Co., Ltd.